Çocuklarda kolestatik tip hepatit A enfeksiyonu

Çalışmamızın amacı çocukluk yaş grubupda kolestatik hepatit A enfeksiyonunun klinik seyrini ve prognozunu değerlendirmektir. Haziran 1998 ile Mayıs 2002 tarihleri arasında akut hepaüt A enfeksiyonu nedeniyle hastaneye yatırılan 33 çocuk hasta retrospektif olarak değerlendirildi. Direkt bilirubin düzeyi total bilirubinin %50'sinden fazla ve total bilirubini en az dört hafta süreyle 10 mg/dl'nin üzerinde olan hastalar kolestatik hepatit olarak tanımlandı. Hastaneye yatırılan hepatit A hastalarından beş hasta (%15.2) kolestatik hepatit tanısı aldı. Bu beş hastanın birinde akut hepatit A enfeksiyonunun iki varyantı olan relapsing ve kolestatik form birlikte mevcuttu. Hastalarda saptanan bulgular uzamış sarılık, kaşıntı ve hepatomegali idi. Tüm vakalarda kolestatik bulgular ön planda idi ve bilirubin düzeyleri 24-45 mg/dL arasında değişiyordu. Üç hastada protrombin zamanı uzundu ve K vitamini tedavisi ile normale döndü. Dört hasta ursodeoksikolik asit, bir hasta ise ursodeoksikolik asit tedavisi yanısıra kısa süreli prednizolon tedavisi aldı. Hastalarda sekelsiz tam iyileşme görüldü. Çocuklarda kolestatik tip hepatit'A enfeksiyonu nadir görülen benign bir hastalık formudur, Hepatit A enfeksiyonunun bu nadir formunun bilinmesi, obstrüktif sarılıktan şüphe edilen hastalarda gereksiz invaziv işlemlerin uygulanmasını engelleyebilir.

Cholestatic hepatitis A infection during childhood

The aim of this study was to evaluate the clinical evolution and prognosis of cholestatic hepatitis A during childhood. A retrospective study of 33 children hospitalized for acute hepatitis A infection between June 1998 and May 2002 were studied. Cholestauc hepatitis was defined by a direct bilirubin higher than 50% of the total bilirubin and serum bilirubin levels greater than 10 mg/dL during at least 4 weeks. Five cases were identified, which represents 15.2% of all hospitalized hepatitis A cases. One of the five cases had a combination of the two variants of acute viral hepatitis A, the relapsing and cholestatic forms. Physical findings include prolonged jaundice, pruritis and hepatomegally. Cholestatic symptomatology was predominant in all cases with bilirubih values ranging from 24 to 45 mg/dL. Prolonged prothrombin times, corrected with vitamin K, were seen in three of these patients. Four patients were treated with ursodeoxycholic acid, one patient with ursodeoxycholic acid plus short-term pretinisbne therapy- All patients recovered completely without sequelae. Cholestatic hepatitis is an infréquent and benign form of acute hepatitis A in childhood. Knowledge of this unusual manifestation of hepatitis A may help avoid potentially invasive procedures involved in the evaluation of suspected obstructive jaundice.

___

1. Kanra G, Kara A. Hepatit A virüsü ve hepatit A. Katkı Pediatri Dergisi 1998; 19: 577-593. 2. Ciocca M. Clinical course and consequences of hepa¬ titis A infection. Vaccine 2000;18(suppl 1): 71-74. 3. Maier KP. Clinical significance of cholestatic viral he¬ patitis. Z Gastroenterol 1993;31(suppl 2): 71-72. ' 4. Gordon SC, Reddy KR, Sehiff L, et al. Prolonged intra-hepatic cholestasis secondary to acute hepatitis A. Ann Intern Med 1984; 101: 635-637. 5. Molina Merino A, Martinez-Huguet F, Asensi Monzo MT, et al. Cholestatic-type hepatitis in childhood. An Esp Pediatr 1998; 49: 253-256. 6. Corpechot C, Cadranel JF, Hoang C, et al. Cholesta¬ tic viral hepatitis A in adults. Clinical, biological and histopathological study of 9 cases. Gastroenterol Clin Biol 1994;18: 743-750. 7. Stiehl A, Rudolph G, Raedsch R, et al. Ursodeoxycho- lic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepa- tology 1990; 12: 492-497. 8. Galle PR, Theilrriann L, Raedsch R, et al. Ursodeoxyc- holate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 1990:12:486-491. 9. Fabris P, Tositti G, Mazzella G, et al. Effect of ur-sodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study. Aliment Pharmacol Ther 1999; 13:1187-1193. 10. Galsky J, Bansky G, Holubova T, et al. Effect of ur- sodeoxycholic acid in acute viral hepatitis. J Clin Gastroenterol 1999; 28: 249-253. 11. Koçak N, Saltık İN. The effect of ursodeoxycholic acid in children with prolonged hepatitis A virus infection that may be a trigger factor for autoimmune hepatitis. Am J Gastroenterol 2001; 96: 610-611. 12. Dinler G, Koçak N, Özen H, et al. Ursodeoxycholic acid treatment in children with Byler disease. Pediatr Int 1999; 41: 662-665. 13. Williams R, Billing BH. Action of steroid therapy in jaundice. Lancet 1961; 2: 392-396. 14. KoffRS. Hepatitis A. Lancet 1998; 351: 1643-1649. 15. Sehiff L. The use of steroids in liver disease. Medicine (Baltimore) 1966; 45: 565-573. 16. Rachima CM, Cohen E, Garty M. Acute hepatitis A: Combination of the relapsing and the cholestatic forms, two rare variants. Am J Med Sci 2000; 319: 417-419. 17. Glikson M, Galun E, Ören R, et al. Relapsing hepati¬ tis A. Review of 14 cases and literature survey. Medicine (Baltimore) 1992; 71: 14-23. 18. Sehiff ER. Atypical clinical manifestations of hepatitis A. Vaccine 1992; 10(suppl 1): 18-19. 19. Teixeira MR Jr, Weller IV, Murray A, et al. The pat¬ hology of hepatitis A in mart. Liver 1982; 2: 53-60.

20. Ramonet MD, Gomez S, Morise S, et al. Acute hepati¬ tis A virus. Association with fulminant hepatic failure and autoimmune hepatitis in pediatric population. J Pediatr Gastroenterol Nutr 2000; 31(suppl 2): 116-117. 21. Hilzenrat N, Zilberman D, Klein T, et al. Autoimmune hepatitis in a genetically susceptible patient: is it trig¬ gered by acute viral hepatitis A? Dig Dis Sci 1999; 44: 1950-1952. 22. Akbulut A. HAV enfeksiyonu. Kılıçturgay K, Badur S. Viral Hepatit 2001 (1. Baskı). Viral Hepatitle Savaşım Derneği Yayını, 2001: 70-71.